Current medicinal chemistry

ISSN 1875-533X

2 papers in the library · 70 citations · publishing 2002-2025

Papers

A review of chemical agents in the pharmacotherapy of addiction.

Current medicinal chemistry October 1, 2002 M S Levi, R F Borne 70 citations

Ibogaine, a naturally occurring alkaloid, has been reported to interrupt cravings for alcohol, cocaine, and opiates. Other alkaloids from Tabernanthe iboga, such as ibogamine and tabernanthine, offer insights into structure-activity relationships at receptors involved in addiction. The synthetic congener 18-MC shows potential as an anti-addictive agent without ibogaine's hallucinogenic effects. Acamprosate, BP 897, GBR12909, lofexidine, and memantine have also shown promising results. Currently, no drugs are approved in the U.S. for treating addictions to cocaine, methamphetamine, other stimulants, or PCP.

DOI: 10.2174/0929867023368980 Full text Anti-addiction medications Substance abuse treatment Drug treatment Craving reduction +13

MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years.

Current medicinal chemistry June 2, 2025 Jinlong Zhang, Xingxing Dang, Jiang Lin et al.

A bibliometric analysis of 30 years of research on MDMA-assisted therapy for PTSD, anxiety, and depression shows a substantial increase in publications over the past decade. The United States leads in output, the Multidisciplinary Association for Psychedelic Studies (MAPS) is the most productive institution, and Rick Doblin is a highly influential researcher. The research focus has shifted from studying MDMA's neurotoxicity to exploring its therapeutic mechanisms, safety, and clinical applications. The analysis identifies key research trajectories and challenges, including the need for improved trial design, greater sample diversity, and evaluation of long-term effects to support clinical integration.

DOI: 10.2174/0109298673359474250511181821 Full text Anxiety Depression Psychedelic therapy Literature analysis. +4